-
NEJM Publishes and Then, in the Same Edition, Challenges a Company-sponsored Study Article
A Classic Example of Medical Journal Manipulation by Pharmaceutical Industry? In the August 4, 2005 edition of the New England Journal Of Medicine, an editorial piece seems to cast some doubt on a research…
-
What Does Direct-to-Consumer Advertising Have to Do with Prescription Drug Clinical Trials?
Major Medical Journals Lead Us Astray by Publishing Studies Designed to Help Sell Product for the Drug Company Today, Richard Smith is Chief Executive of UnitedHealth Europe, in London. Previously, Mr. Smith was an…
-
FDA Chief Dr. Lester Crawford is Criticized on Drug-safety Issues
Vioxx Case Puts Spotlight on FDA’s Monitoring of Emerging Drug Side Effects At a July 26, 2005 hearing before a House of Representatives appropriations subcommittee, Dr. Lester Crawford, the new head of the FDA,…
-
Celebrex “Black Box” Label Warning About Increased Cardiovascular Risks
"Class Effect": Like Bextra and Vioxx, Celebrex Can Cause Heart Attacks and Strokes The pharmaceutical company Pfizer Inc. announced on August 1, 2005 that the FDA had finalized a new label for the arthritis…
-
Hormonal Menopausal Therapy Classified as Carcinogenic by IARC
U.N. Research Agency Determines Hormone Therapy Regimen Slightly Raises Risk of Some Cancers In late July 2005, the International Agency for Research on Cancer — the United Nations’ cancer agency — announced its new…
-
Vioxx-related Heart Attack Risk Increased After Just A Few Weeks Use, Not 18 Months?
"New" Liability Document Will be Important In NJ Vioxx Case Scheduled for September 2005 On July 26, 2005 The Wall Street Journal reported that plaintiff attorneys in a New Jersey Vioxx lawsuit are expected…
